ArticleJournal of medical imaging and radiation oncology2026
SpyGlass-Assisted Percutaneous Transhepatic Cholangioscopy in Patients With Biliary Duct Calculi: A Retrospective Cohort Study From an Australasian Centre.
Article in Journal of medical imaging and radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPercutaneous transhepatic cholangioscopy has emerged as a viable alternative to endoscopic retrograde cholangiopancreatography for the management of biliary duct calculi. This study aimed to evaluate the outcomes of treating biliary duct calculi using SpyGlass-assisted percutaneous transhepatic cholangioscopy.
methodsA retrospective review was conducted of all patients who underwent SpyGlass-assisted percutaneous transhepatic cholangioscopy at a single-centre between May 2021 and December 2024. Demographic, clinical, imaging, procedural, and adverse event data were collected from electronic medical records. The primary outcome was clinical success, defined as complete resolution of presenting symptoms with associated improvement in biochemical markers. The secondary outcome was technical success, defined as complete clearance of biliary duct calculi on direct visualisation using SpyGlass cholangioscopy and fluoroscopic imaging. Adverse events were recorded and classified according to severity using the Clavien-Dindo classification.
resultsBetween May 2021 and December 2024, 27 patients underwent 42 SpyGlass-assisted percutaneous transhepatic cholangioscopy procedures for 32 distinct clinical presentations. Clinical success was achieved in all presentations, and technical success was recorded at 83% of procedures. Adverse events occurred in 36% of procedures, the majority of which were minor (Clavien-Dindo classification Grade 1 or 2). There was a single case of procedure-related mortality.
conclusionSpyGlass-assisted percutaneous transhepatic cholangioscopy appears to be a safe and effective alternative for the management of biliary duct calculi, particularly in cases where endoscopic retrograde cholangiopancreatography is unsuccessful or contraindicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.